No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BDX240517C235000
- 2.60
- -0.40-13.33%
15min DelayClose May 9 15:59 ET
3.10High2.60Low
3.10Open3.00Pre Close251 Volume1.56K Open Interest235.00Strike Price75.29KTurnover17.12%IV1.06%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry2.60Time Value100Contract SizeAmericanOptions Type0.5230Delta0.0672Gamma94.00Leverage Ratio-0.1712Theta0.0261Rho49.16Eff Leverage0.1379Vega
Intraday
- 5D
- 1D
News
Express News | NYSE Order Imbalance 58037.0 Shares on Buy Side
Express News | NYSE Order Imbalance 86851.0 Shares on Sell Side
Becton Dickinson Is Maintained at Overweight by Barclays
Becton Dickinson Is Maintained at Overweight by Barclays
Becton Dickinson Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 32.95% Barclays $305 → $312 Maintains Overweight 02/05/2024 29.96% Barclays $301 → $305 Maintai
11 Best Recession Dividend Stocks To Buy
Barclays Adjusts Price Target on Becton, Dickinson to $312 From $305, Keeps Overweight Rating
Becton, Dickinson (BDX) has an average outperform rating and a price target range of $240 to $325, according to analysts polled by Capital IQ. Price: 237.00, Change: +2.32, Percent Change: +0.99
Comments
$Becton Dickinson & Co(BDX.US$ GAME OVER stock.
Despite a dip in earnings, Becton Dickinson's high P/E ratio persists due to anticipated robust future growth, outpacing the broader market. Investors' confidence in the company's future earnings is high, indicating the share price is unlikely to drop significantly soon.
$Becton Dickinson & Co(BDX.US$ BD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device
2
Dr. Silverman's extensive experience and zeal for innovation, evidence generation, clinical development, medical safety, and compliance is predicted to boost BD's innovation pipeline and foster improved, personalized care.
Market sentiment towards Becton, Dickinson and Company shows no major shift in the past year. However, the rise in total shareholder return hints at a growing positivity.
Read more